Middle East conflict impact on ROW business
Saudi Arabia shipments paused due to geopolitical tensions, causing a dip in ROW revenue; recovery uncertain.
medium · management_commentaryGland Pharma Limited — Q4 FY26
Gland Pharma reported a strong Q4 FY26 with consolidated revenue of INR 17,428 million (+22% YoY) and adjusted EBITDA margin of 30% (+500bps YoY), driven by robust CDMO growth (...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Raw material cost inflation from glass/solvent
Suppliers requesting 5-6% price increase for vials/glass; potential 1-2% impact on overall costs.
low · management_commentaryGLP-1 revenue timing uncertainty
Management excludes GLP-1 from guidance due to dependency on partner approvals and market launches, creating upside risk but also uncertainty.
medium · analyst_questionCenexi revenue growth may lag expectations
Despite capacity additions, Cenexi revenue growth may be modest in FY27 as new lines ramp up slowly; focus on profitability over top line.
low · analyst_question